Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab induction and maintenance in moderately to severely active ulcerative colitis
NL-OMON44076Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Dec 2015; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON44076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44076.